/home/ejo ORIGINAL RESEARCH ARTICLE seriouscomplications-suchasuveitis,glaucoma,andcornealendothelialdamage-limitedtheuseofsuchdevices(5-8).
Introduction
Aniridia, whether congenital or traumatic, can lead to reduced visual acuity and other visual disturbances such as glareandphotophobia.Also,patientsperceivesuchirisdefectsasacosmeticproblem.Treatmentoptionsincludecolored contact lenses, corneal tattooing, and corneal stromal implants,whichhavelimitationsandrisks (1) .
Variousstudieshavebeenpublishedreportingtheuseof multiple iris prosthetic devices; however, none is currently approved for use in the United States (2, 3) . Koch et al (4) reportedtheuseofmedicallyindicatedartificialiristotreat aniridia(DrSchmidtIntraocularlinsen,GmbH,HumanOptics AG).ColorIrisimplants(KahnMedicalDevices)wereactively promoted as cosmetic devices to change iris colors, but
Preoperative examination
All patients underwent a full ophthalmic examination includinguncorrecteddistancevisualacuity(UCDVA)andbestcorrected distance visual acuity (BCDVA) in logMAR, slit-lamp examination,gonioscopy,intraocularpressure(IOP)measurement,andfundusexamination.Intraocularlenspowercalculationandwhitetowhite(W-W)measurementwasdoneusing IOLMaster (Carl Zeiss Meditec). Specular microscopy was done in all cases using SP 3000 P (Topcon Inc.).
Theirisimplantscomeindifferentsizes:12.5,12.75,13, and 13.25 mm. We chose the implant size by adding 0.5 mm to W-W measurement.
Surgical technique
All patients were operated under general anesthesia. Afterdisinfectionoftheperiocularareaanddraping,aspeculum was placed. A 3.2-mm clear corneal incision was made on thesteepaxiswheneverpossible.Inonecase(5),acapsule tensionringwasusedinaddition.
In the 2 aphakic cases (1 and 4), anterior vitrectomy was done,followedbyscleralsuturefixationoftheSensar3-piece IOL with a 13-mm overall diameter in the sulcus.
AftersecuringtheIOLinplaceinallcases,theirisprosthesiswasremovedfromthebalancedsaltsolutionaftersoakingfor5minutes.Wecouldeasilyidentifytheanteriorfrom posterior surface by the ridges on posterior surface and iris patternonanteriorsurface.Theimplantwasfoldedusinga McPherson forceps and was implanted through a 3.2-mm incisionwiththeanteriorchamberfilledwithHealonGV. During unfolding of the implant, an iris spatula was introduced through a paracentesis to help unfolding of the implant and to protect the corneal endothelium from contact with the unfolding implant. In one case, the implant was rolled and introduced successfully into the anterior chamber using the same cartridgeandinjectorusedforimplantationofahydrophilic acrylic IOL through a 3.2-mm incision.
In all cases, the implant was placed in the sulcus in front of the IOL and behind any iris remnants. In one case, only primary suturing of the implant to the sclera from upper pole was done using a 10/0 Prolene suture after noticing itsinstabilityanddecentrationandunavailabilityofalarger implant.
Postoperative examination
Examination was done at the first postoperative day, at 1week,1month,3months,and6monthspostoperatively. The medical records were evaluated for changes in visual acuityasafunctionalparameterandforIOPvaluestoassess secondary glaucoma, endothelial cell count (ECC), and central corneal thickness (CCT) as quantitative parameters for the conditionofthecornea.Postoperativeslit-lampphotography and ultrasonic biomicroscopy were done to evaluate iris implantcentrationandcontactwithuvealstructures.
Results
Thestudyreviewed5eyesof4patients.
Case 1
A 12-year-old boy had left aphakia and total aniridia withahistoryofrepairedrupturedglobeandlensextraction 1 year earlier. Slit-lamp examination showed a paracentral oblique corneal scar, aphakia with no capsular support,andatotalirisdefect.HisUCDVAwas1.3andBCD-VA was 0.5. The ECC was 2,100 cells/mm 2 ,CCTwas590μm, anterior chamber depth (ACD) was 3.00 mm, and W-W measurement was 12 mm. His IOP was 16 mm. Surgery included anterior vitrectomy, scleral suture fixation of Sensar 3-piece IOL, and placement of iris prosthesis through a 3.2 mm incision in front of the IOL in the sulcus without suturing.
Onthefirstdaypostoperatively,theeyehadmildsubconjunctivalhemorrhage,moderatecornealstromaledema,and awell-centeredIOLandirisprostheticimplant.
One week postoperatively, UCDVA was 0.6 and BCDVA was 0.3. The cornea was clear, IOP was 18 mm Hg without medical treatment, and iris prosthesis was well-centered. The patient and the parents were satisfied with the cosmeticresults.
There was an IOP spike after 2 weeks that necessitated the use of single topical antiglaucoma eyedrops (Betaxolol 0.5%)bid,usedfor1monthuntilthepressurewentbackto normalwithoutmedication.
The patient was last seen after 6 months from surgery withthesamevisualacuity,IOP,andcosmeticsatisfaction.
Cases 2 and 3 (same patient)
A 13-year-old girl with congenital aniridia and congenital subluxatedcataractouslensinbotheyeswasreferredtoour centerforlensectomyandartificialirisimplantation.PreoperativeUCDVAwas1.3intherighteyeand1.22inthelefteye. Intraocularpressurewas18and16mmHginrightandleft eyes, respectively, and ECC was 2,300 and 2,400 cells/mm 2 forrightandlefteyes,respectively.
The right eye was operated, followed 1 week later by thelefteye.Carefulcapsulorhexiswasinitiatedawayfrom thesubluxationwithextensivehydrodissectionandhydration of the cortical contents, followed by phacoaspiration of the soft nucleus and bimanual irrigation-aspiration of the residual cortex. The Sensar IOL optic was captured in theanteriorcapsulorhexis,leavingthehapticsintheciliary sulcus.IrisimplantationwasthendoneovertheIOLinthe sulcus.
One week postoperatively, the UCDVA was 0.8 in the righteyeand0.6inthelefteye.TheIOPwas28mmHgin the right eye and 30 in the left eye. Topical antiglaucoma eyedrops were given to lower IOP (combined 10 mg/mL brinzolamideand5mg/mLtimololmaleate)bid.Slit-lamp examinationshowedmilduveitisandmildcornealedema. Theirisimplantwascenteredandwell-positionedinboth eyes.Threemonthspostoperatively,theUCDVAwas0.5in both eyes. The IOP was 14 and 15 mm Hg in the right and left eyes, respectively, under topical medical treatment. Faint band-shaped keratopathy started to develop in both eyes1yearafterthesurgery(moredenseonthelefteye). See Figure 1 .
Case 4
A 28-year-old man with right aphakia and total aniridia had a history of repaired rupture globe and lens extraction 6 months previously, performed elsewhere.
Slit-lampexaminationshowedaparacentrallongitudinal scar, aphakia with no capsular support, and total aniridia. Intraocular pressure was 14 mm Hg. The UCDVA was 1.3 and BCDVA was 0.5. The ECC was 1,569 cells/mm 2 , CCT was 585 μm, ACD was 2.94 mm, and W-W was 11.7 mm. After automatedanteriorvitrectomy,ascleralsuturefixationofa 3-piece Sensar IOL was done using a 10/0 Prolene suture and the artificial iris was implanted in the ciliary sulcus without sutures. On the first postoperative day, the iris prosthesis showedinferiordisplacementandthepatientwasreadmitted and readjustment was done in the same day under topical anesthesia without scleral sutures.
One week postoperatively, the patient presented with pain,nausea,andvomitingandseverecornealedema.TheIOP was44mmHgandvisionmarkedlydroppedtoUCDVAof1.3. Medical treatment was prescribed to control IOP in the form of topical combined 10 mg/mL brinzolamide and 5 mg/mL timolol maleate and oral acetazolamide 250 mg/6 hours, whichwasgraduallytaperedoverthenext4weeks.
At1month,theUCVAwas0.8,IOPwas20mmHgontopi-calantiglaucomamedications,andtheimplantshowedmild inferior displacement.
Threemonthspostoperatively,IOPwas16mmHgunder topical monotherapy (combined 10 mg/mL brinzolamide and 5mg/mLtimololmaleatebid),thecorneawasclear,andthe visionmarkedlyimprovedtoUCDVAof0.6,buttheirisprosthesis showed marked inferior displacement. Being the second time of displacement, 10/0 Prolene sutures were used tofixtheirisprosthesisintheciliarysulcusandtiedundera scleralflap.
Sixmonthspostoperatively,visualacuityshowedfurther improvement.TheUCVAwas0.5andBCDVAwas0.22.The IOP was 18 mm Hg on no treatment. The iris prosthesis was well-positionedandcentered.SeeFigure2.
Case 5
A 34-year-old woman had a left subluxated crystalline lens with a posterior subcapsular cataract and a large iris defectextendingfor6clockhoursfollowingresectionofacili-arybodymelanoma6monthsearlier.Hergeneralcondition wasstablewithnosignsofocularorsystemicmanifestations of the melanoma. Her UCDVA was 1.52 in the affected eye and BCDVA was 0.5. The ECC was 1,714 cells/mm 2 , CCT was 540 μm, ACD was 3.50 mm, and W-W measurement was 12.5 mm. Phacoaspiration through a 3.2-mm clear corneal incisionwasdonefollowedbytheimplantationofacapsule tension ring and a 3-piece Sensar lens was implanted capturingtheopticintheanteriorcapsulorhexisandthehapticsin theciliarysulcus.Thiswasfollowedbyimplantationoftheiris prosthesisintheciliarysulcusandtheprosthesiswasfixedto the sclera with one 10/0 Prolene suture into the ciliary sulcus (1.5mmbehindthelimbus)withtheknottiedunderascleral 
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flap.Thesuturewastakenastheprosthesiswasundersized and unstable in the sulcus and there was no larger implant available.
Earlypostoperativecoursewasuneventfulwithclearcornea, centered prosthesis with well-centered IOL, and normal IOPatthefirstday.
Onemonthpostoperatively,UCDVAwas0.6andBCDVA was 0.3 with a well-centered implant and normal IOP. At 3 months, the UCVA dropped to 0.8 and BCDVA was 0.5. Clinically significant posterior capsular opacification was detected.
Six months postoperatively, YAG laser posterior capsulotomywasdonethroughtheimplantaperture.TheUCDVA improvedto0.6andBCDVAto0.3,theimplantwasstillwellcentered, and IOP was 15 mm Hg.
Discussion
Aniridiaisachallengingsurgicalsituation.Patientswith aniridiahavebothanopticalaswellasacosmeticproblem. Many methods have been advocated to manage this condition(9-11).Theuseofartificialirisprosthesisisoneofthe best ways to tackle the problem. Today there are 2 known artificialirisprosthesisavailable:TheHumanOptics(formerly Dr.SchmidtIntraocularlinsen),whichisinvestigatedcurrentlyinamulticenterclinicaltrial,andBrightOcular(usedinour study). Both of them are made of silicone and are designed to be placed in the sulcus in aphakic or pseudophakic patients.TheHumanOpticsprosthesishasbeenusedforyears and has the advantage of being custom-made as regards the color and iris pattern of the patient. The BrightOcular prosthesis comes in certain colors, from which the surgeon chooses according to the color of the patient's other eye. ThereforeTheHumanOpticsprosthesisisassociatedwithsuperiorcosmeticresults(4).
TheHumanOpticsprosthesiscomesinonesize(13mm) and should be cut manually to the size needed according totheW-WmeasurementofeachpatientwhiletheBrightOcular implant comes in various sizes (12 to 13 mm) with 0.25-mm increments that makes it easier to choose the best size for each patient. In both prostheses, the size of the implant is recommended to be chosen by adding 0.5 mm to the measured W-W value. Sizing technique needs to be improved to ensure proper placement in the sulcus to avoid any displacements or pressure on the ciliary body. In our study, we had one case of spontaneous displacementoftheprosthesisafter3months,whichneeded repositioning and suturing to the sclera. In another case, therewasintraoperativedisplacementthatrequiredsuturing to the sclera immediately. Both cases were attributed to improper sizing and hence the importance of this step to be planned preoperatively. Nevertheless, in both sutured cases and the rest of the cases, the iris prosthesis remained stable and well-positioned for the rest of the follow-up period.
Srinivasan and others (2) reported placement of HumanOptics prosthesis in the capsular bag after trimming in casescombinedwithcataractextraction.
One of the main issues in placing the iris prosthesis in thesulcusisthepostoperativeincreaseinIOP.Thisiscould beattributedtopressureoftheedgesofprosthesisonthe ciliarybodyinducingalowgradeinflammationand/orentrapment of aqueous behind the implant compromising the angle.
Koch et al (4) reported overcoming this problem with multipleperipheraltrephinepunchesattheperimeterofthe implant.
Inourstudy,wehadapostoperativeriseofIOPin4out of5caseswithdifferentpresentations.Inthe2casesother than the congenital aniridia patient, the rise was transient. Thismightbeattributedtoacongenitaldefectintheangle of the anterior chamber as well as the reported secondary glaucoma in cases of congenital aniridia undergoing cataractextraction.Thebandkeratopathythatdevelopedinthe same patient can also be explained by the limbal stem cell deficiency and aniridia-associated keratopathy documented and reported in those cases, rather than being related to the implant.
Asregardseffectoncornealendothelium,therewereno findingspostoperativelyshowinginsultfromtheprosthesis on corneal endothelium as all cases were pseudophakic at thetimeofimplantationwithadeepanteriorchamber(AC) and implant is away from corneal endothelium. The possible insult to corneal endothelium can occur intraoperatively during implantation and unfolding of the prosthesis. We recommendtheuseofadispersiveviscoelastictocoat the endothelium and high viscosity cohesive viscoelastic to maintain the space in the AC that allows unfolding away from the endothelium.
Inourstudy,allpatientsreportedsatisfactionwiththe cosmetic results and marked improvement in glare and halos.
Moreresearchshouldbedonetofindthebestmeansof sizing the implant and to address the problem of postoperativeIOPrise.Furtherstudiesshouldalsoevaluatethesafety of the prosthesis in clear phakic eyes.
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